3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Basal Cell
3
Margins of Excision
2
Barrett Esophagus
2
Urologic Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Prostatic Neoplasms
1
Pancreatic Cyst
1
Nevus, Pigmented
1
Nephrolithiasis
1
Multicystic renal dysplasia, bilateral
1
Melanoma
1
Lung Neoplasms
1
Lung Diseases
1
Hematuria
1
Esophageal Neoplasms
1
Benign Neoplasm of Liver and/or Biliary Ducts
1
Adenocarcinoma
1
Interventions
Gemcitabine
9
pembrolizumab
7
Cisplatin
5
enfortumab vedotin
4
atezolizumab
4
Trastuzumab
4
Carboplatin
4
Sunitinib
3
Pemetrexed
3
Mitomycin
3
cabozantinib
2
Water
2
Sugammadex
2
Standard of Care
2
Saline Solution
2
Paclitaxel
2
Nivolumab
2
Neostigmine
2
Docetaxel
2
Cetuximab
2
Bevacizumab
2
zidovudine 5'-monophosphate-mannose-albumin conjugate
1
vinflunine
1
valrubicin
1
tucatinib
1
tislelizumab
1
testosterone 17 beta-cypionate
1
temsirolimus
1
relatlimab
1
poly ICLC
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Urologic Neoplasms
×
Microscopy, Confocal
×
Clear all
NCT02276924
2025-12-24
UROVISIO
Lille Catholic University
Phase NA
Completed
29 enrolled